Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lantern Pharma Inc (LTRN)

Lantern Pharma Inc (LTRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,940
  • Shares Outstanding, K 11,184
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,780 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.25

Options Overview Details

View History
  • Implied Volatility 635.77% (+297.11%)
  • Historical Volatility 76.94%
  • IV Percentile 99%
  • IV Rank 82.93%
  • IV High 749.32% on 11/12/25
  • IV Low 84.29% on 07/22/25
  • Expected Move (DTE 12) 0.21 (5.67%)
  • Put/Call Vol Ratio 2.88
  • Today's Volume 202
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 1,445
  • Open Int (30-Day) 1,499
  • Expected Range 3.54 to 3.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +185,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.86 +31.12%
on 11/21/25
3.93 -4.58%
on 11/26/25
+0.20 (+5.63%)
since 11/05/25
3-Month
2.86 +31.12%
on 11/21/25
4.70 -20.27%
on 10/08/25
-0.56 (-12.99%)
since 09/05/25
52-Week
2.55 +47.06%
on 04/08/25
6.12 -38.71%
on 01/24/25
+0.25 (+7.14%)
since 12/05/24

Most Recent Stories

More News
Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights...

LTRN : 3.75 (-0.53%)
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all primary...

LTRN : 3.75 (-0.53%)
Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress

Lantern Pharma (NASDAQ: LTRN) reported third-quarter 2025 results and advanced multiple AI-driven oncology programs, highlighted by completion of enrollment and achievement of all primary endpoints in...

LTRN : 3.75 (-0.53%)
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch LP-184 Phase 1a...

LTRN : 3.75 (-0.53%)
Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE

• Lantern’s AI platform “learns, reads, models, and predicts” to identify new drugs and indications • CEO Panna Sharma says AI is compressing development timelines and cost structures across...

LTRN : 3.75 (-0.53%)
New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST

NEW YORK CITY, NEW YORK / ACCESS Newswire / November 8, 2025 / New to The Street announces the broadcast of Show Number 698, airing on Bloomberg Television this Saturday, November 8, 2025, at 6:30 PM EST,...

LTRN : 3.75 (-0.53%)
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows

NEW YORK, NY / ACCESS Newswire / November 7, 2025 / New to The Street, one of America's leading business television and multi-platform media brands, today announced a comprehensive media partnership with...

LTRN : 3.75 (-0.53%)
Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments

Lantern Pharma (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR(R) platform, will host a webcast at 9 a.m. ET (6 a.m. PT) on Thursday, Nov. 13, 2025,...

LTRN : 3.75 (-0.53%)
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

Webcast to be held Thursday, November 13th, 9:00 a.m. ET, register for the webcast here , or at the link provided below.

LTRN : 3.75 (-0.53%)
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. ...

LTRN : 3.75 (-0.53%)

Business Summary

Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.

See More

Key Turning Points

3rd Resistance Point 4.18
2nd Resistance Point 4.04
1st Resistance Point 3.89
Last Price 3.75
1st Support Level 3.61
2nd Support Level 3.47
3rd Support Level 3.33

See More

52-Week High 6.12
Fibonacci 61.8% 4.76
Fibonacci 50% 4.33
Fibonacci 38.2% 3.91
Last Price 3.75
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar